PortalPublikationenImpact of high-risk cytogenetics and achievement of molecula...

Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.

Standard

Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. / Kröger, Nicolaus-Martin; Badbaran, Anita; Zabelina, Tatiana; Ayuketang, Francis Ayuk; Wolschke, Christine; Alchalby, Haefaa; Klyuchnikov, Evgeny; Atanackovic, Djordje; Schilling, Georgia; Hansen, Timon; Schwarz, Sabine; Heinzelmann, Marion; Zeschke, Silke; Bacher, Ulrike; Stübig, Thomas; Fehse, Boris; Zander, Axel R.

in: BIOL BLOOD MARROW TR, Jahrgang 19, Nr. 3, 3, 2013, S. 398-404.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kröger, N-M, Badbaran, A, Zabelina, T, Ayuketang, FA, Wolschke, C, Alchalby, H, Klyuchnikov, E, Atanackovic, D, Schilling, G, Hansen, T, Schwarz, S, Heinzelmann, M, Zeschke, S, Bacher, U, Stübig, T, Fehse, B & Zander, AR 2013, 'Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.', BIOL BLOOD MARROW TR, Jg. 19, Nr. 3, 3, S. 398-404. https://doi.org/10.1016/j.bbmt.2012.10.008

APA

Kröger, N-M., Badbaran, A., Zabelina, T., Ayuketang, F. A., Wolschke, C., Alchalby, H., Klyuchnikov, E., Atanackovic, D., Schilling, G., Hansen, T., Schwarz, S., Heinzelmann, M., Zeschke, S., Bacher, U., Stübig, T., Fehse, B., & Zander, A. R. (2013). Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. BIOL BLOOD MARROW TR, 19(3), 398-404. [3]. https://doi.org/10.1016/j.bbmt.2012.10.008

Vancouver

Kröger N-M, Badbaran A, Zabelina T, Ayuketang FA, Wolschke C, Alchalby H et al. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. BIOL BLOOD MARROW TR. 2013;19(3):398-404. 3. https://doi.org/10.1016/j.bbmt.2012.10.008

Bibtex

@article{81f1a06d4d1146e383dacad102fbcb7a,
title = "Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.",
abstract = "Within a prospective protocol, the incidence and impact of achievement of molecular remission (mCR) and high-risk cytogenetics was investigated in 73 patients with multiple myeloma (MM) after autologous (auto)-allogeneic (allo) tandem stem cell transplantation (SCT). After induction chemotherapy, patients received melphalan 200 mg/m(2) before undergoing auto-SCT, followed 3 months later by melphalan 140 mg/m(2) and fludarabine 180 mg/m(2) before allo-SCT. Sixteen patients had high-risk cytogenetic features, defined by positive FISH for del(17p13) and/or t(4;14). Overall, 66% of the patients achieved CR or near-CR, and 41% achieved mCR, which was sustained negative (at least 4 consecutive samples negative) in 15 patients (21%), with no significant difference in incidence between the patients with high-risk cytogenetics and others (P = .70). After a median follow-up of 6 years, overall 5-year progression-free survival was 29%, with no significant difference between del 17p13/t(4;14)-harboring patients and others (24% versus 30%; P = .70). The 5-year progression-free survival differed substantially according to the achieved remission: 17% for partial remission, 41% for CR, 57% for mCR, and 85% for sustained mCR. These results suggest that auto-allo tandem SCT may overcome the negative prognostic effect of del(17p13) and/or t(4;14) and that achievement of molecular remission resulted in long-term freedom from disease.",
keywords = "Adult, Cytogenetic Analysis, Disease-Free Survival, Female, Hematopoietic Stem Cell Transplantation, Humans, Male, Melphalan, Middle Aged, Multiple Myeloma, Myeloablative Agonists, Prognosis, Prospective Studies, Remission Induction, Translocation, Genetic, Transplantation Conditioning, Transplantation, Autologous, Transplantation, Homologous, Treatment Outcome, Vidarabine",
author = "Nicolaus-Martin Kr{\"o}ger and Anita Badbaran and Tatiana Zabelina and Ayuketang, {Francis Ayuk} and Christine Wolschke and Haefaa Alchalby and Evgeny Klyuchnikov and Djordje Atanackovic and Georgia Schilling and Timon Hansen and Sabine Schwarz and Marion Heinzelmann and Silke Zeschke and Ulrike Bacher and Thomas St{\"u}big and Boris Fehse and Zander, {Axel R}",
note = "Copyright {\textcopyright} 2013. Published by Elsevier Inc.",
year = "2013",
doi = "10.1016/j.bbmt.2012.10.008",
language = "English",
volume = "19",
pages = "398--404",
journal = "BIOL BLOOD MARROW TR",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.

AU - Kröger, Nicolaus-Martin

AU - Badbaran, Anita

AU - Zabelina, Tatiana

AU - Ayuketang, Francis Ayuk

AU - Wolschke, Christine

AU - Alchalby, Haefaa

AU - Klyuchnikov, Evgeny

AU - Atanackovic, Djordje

AU - Schilling, Georgia

AU - Hansen, Timon

AU - Schwarz, Sabine

AU - Heinzelmann, Marion

AU - Zeschke, Silke

AU - Bacher, Ulrike

AU - Stübig, Thomas

AU - Fehse, Boris

AU - Zander, Axel R

N1 - Copyright © 2013. Published by Elsevier Inc.

PY - 2013

Y1 - 2013

N2 - Within a prospective protocol, the incidence and impact of achievement of molecular remission (mCR) and high-risk cytogenetics was investigated in 73 patients with multiple myeloma (MM) after autologous (auto)-allogeneic (allo) tandem stem cell transplantation (SCT). After induction chemotherapy, patients received melphalan 200 mg/m(2) before undergoing auto-SCT, followed 3 months later by melphalan 140 mg/m(2) and fludarabine 180 mg/m(2) before allo-SCT. Sixteen patients had high-risk cytogenetic features, defined by positive FISH for del(17p13) and/or t(4;14). Overall, 66% of the patients achieved CR or near-CR, and 41% achieved mCR, which was sustained negative (at least 4 consecutive samples negative) in 15 patients (21%), with no significant difference in incidence between the patients with high-risk cytogenetics and others (P = .70). After a median follow-up of 6 years, overall 5-year progression-free survival was 29%, with no significant difference between del 17p13/t(4;14)-harboring patients and others (24% versus 30%; P = .70). The 5-year progression-free survival differed substantially according to the achieved remission: 17% for partial remission, 41% for CR, 57% for mCR, and 85% for sustained mCR. These results suggest that auto-allo tandem SCT may overcome the negative prognostic effect of del(17p13) and/or t(4;14) and that achievement of molecular remission resulted in long-term freedom from disease.

AB - Within a prospective protocol, the incidence and impact of achievement of molecular remission (mCR) and high-risk cytogenetics was investigated in 73 patients with multiple myeloma (MM) after autologous (auto)-allogeneic (allo) tandem stem cell transplantation (SCT). After induction chemotherapy, patients received melphalan 200 mg/m(2) before undergoing auto-SCT, followed 3 months later by melphalan 140 mg/m(2) and fludarabine 180 mg/m(2) before allo-SCT. Sixteen patients had high-risk cytogenetic features, defined by positive FISH for del(17p13) and/or t(4;14). Overall, 66% of the patients achieved CR or near-CR, and 41% achieved mCR, which was sustained negative (at least 4 consecutive samples negative) in 15 patients (21%), with no significant difference in incidence between the patients with high-risk cytogenetics and others (P = .70). After a median follow-up of 6 years, overall 5-year progression-free survival was 29%, with no significant difference between del 17p13/t(4;14)-harboring patients and others (24% versus 30%; P = .70). The 5-year progression-free survival differed substantially according to the achieved remission: 17% for partial remission, 41% for CR, 57% for mCR, and 85% for sustained mCR. These results suggest that auto-allo tandem SCT may overcome the negative prognostic effect of del(17p13) and/or t(4;14) and that achievement of molecular remission resulted in long-term freedom from disease.

KW - Adult

KW - Cytogenetic Analysis

KW - Disease-Free Survival

KW - Female

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Male

KW - Melphalan

KW - Middle Aged

KW - Multiple Myeloma

KW - Myeloablative Agonists

KW - Prognosis

KW - Prospective Studies

KW - Remission Induction

KW - Translocation, Genetic

KW - Transplantation Conditioning

KW - Transplantation, Autologous

KW - Transplantation, Homologous

KW - Treatment Outcome

KW - Vidarabine

U2 - 10.1016/j.bbmt.2012.10.008

DO - 10.1016/j.bbmt.2012.10.008

M3 - SCORING: Journal article

C2 - 23078786

VL - 19

SP - 398

EP - 404

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 3

M1 - 3

ER -